Compare AbCellera Biologics Inc (ABCL) vs Ally Financial Inc (ALLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ally Financial Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Ally Financial Inc trades at $44.13 (market cap $13.92B). The key difference: Ally Financial Inc is far larger — about 5.9× AbCellera Biologics Inc's market cap, and Ally Financial Inc pays a 2.64% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ALLY | |
|---|---|---|
Market Cap | $2.35B | $13.92B |
Sector | Health | Financials |
52-Week High | $8.12 | $47.25 |
52-Week Low | $2.78 | $35.96 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ally Financial (ALLY) trades at $45.40, up 0.18% with strong analyst support (68% buy ratings) and a $54 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q3 2025-Q1 2026. Fundamentals remain solid with a P/E of 11.22 and net income margin of 14.9%, though revenue has declined from $9.2B in 2022 to $8.77B in 2025. Recent corporate developments include a $0.30 dividend payment and upcoming Q2 2026 earnings release on July 21, 2026.
ALLY presents a compelling value opportunity with attractive valuation metrics and consistent earnings outperformance. The primary investment thesis centers on the company's dominant auto lending position and shareholder returns via dividends. Key risks include revenue stagnation, macroeconomic sensitivity to interest rates, and competitive pressure from digital banking disruptors. Upside potential exists if Q2 2026 earnings meet or exceed the $1.26 EPS estimate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →
